ADGC Publications

Found 25 results
2013
Ridge PG, Mukherjee S, Crane PK, Kauwe JSK.  2013.  Alzheimer's disease: analyzing the missing heritability.. PLoS One. 8(11):e79771.
Lin C-F, Otto Valladares, D Childress M, Klevak E, Geller ET, Hwang, ii Y-C, Tsai EA, Gerard D Schellenberg, San Wang L-.  2013.  DRAW+SneakPeek: analysis workflow and quality metric management for DNA-seq experiments.. Bioinformatics. 29(19):2498-500.
Reitz C, Tosto G, Vardarajan B, Rogaeva E, Ghani M, Rogers RS, Conrad C, Haines JL, Pericak-Vance MA, Fallin MD et al..  2013.  Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP).. Transl Psychiatry. 3:e256.
Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, Crehan H, J Gibbs R, Mayeux R, Haines JL et al..  2013.  Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci.. Ann Hum Genet. 77(2):85-105.
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B et al..  2013.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.. Nat Genet. 45(12):1452-8.
Miyashita A, Koike A, Jun G, San Wang L-, Takahashi S, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Arai H et al..  2013.  SORL1 Is Genetically Associated with Late-Onset Alzheimer's Disease in Japanese, Koreans and Caucasians.. PLoS One. 8(4):e58618.
Reitz C, Mayeux R.  2013.  TREM2 and neurodegenerative disease.. N Engl J Med. 369(16):1564-5.
Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BNarayan, San Wang L-, Otto Valladares, Lin C-F, Larson EB, Graff-Radford NR et al..  2013.  Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans.. JAMA. 309(14):1483-92.
2011
Bailey M, Kauwe JSK, Cruchaga C, McKean D, Mayo K, Bertlesen S, Hinrichs A, Fagan A, Holtzman D, Goate AM.  2011.  Association study of recently reported AD risk variants with cerebrospinal fluid AD biomarker levels. AAIC (ICAD) 2011, Paris, France.
Naj AC, Jun G, Beecham GW, San Wang L-, Vardarajan BNarayan, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK et al..  2011.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.. Nat Genet. 43(5):436-41.
Hamilton KL, Naj AC, Park YS, Gallins PJ, Rajbhandary RA, Beecham GW, Martin ER, Haines JL, Pericak-Vance MA.  2011.  Genome-wide Association Analyses Identifies Novel Loci Associated with the Onset Age Among Cases with Late-Onset Alzheimer’s Disease. ASHG/ICHG 2011 (Montreal, Canada).
Kauwe JSK, Cruchaga C, McKean D, Bailey M, Patty D, Mayo K, Bertlesen S, Hinrichs A, Fagan A, Holtzman D et al..  2011.  Genome-wide association analyses using cerebrospinal fluid Aβ42 levels as endophenotype for Alzheimer’s disease. ASHG/ICHG 2011 (Montreal, Canada).
Cruchaga C, Kauwe JSK, McKean D, Bailey M, Patty D, Mayo K, Bertlesen S, Hinrichs A, Peskind E, Li G et al..  2011.  Genome-wide association analyses using cerebrospinal fluid tau and phospho-tau and Aβ42 levels as endophenotypes for Alzheimer’s disease. AAIC (ICAD) 2011, Paris, France.
Jun G, Buros J, Vardarajan BNarayan, Lunetta KL, Farrer LA.  2011.  Genome-wide scan suggested novel Alzheimer disease susceptibility genes by factoring influence of APOE. ASHG/ICHG 2011 (Montreal, Canada).